During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.
Amitkumar Mehta, MD
Director, Lymphoma Program
Assistant Director, Phase I Program
Associate Professor
O’Neal Comprehensive Cancer Center at UAB
Birmingham, AL
TARGETED ONCOLOGY: What is significant about the mechanism of action of loncastuximab tesirine (Zynlonta) in patients with B-cell lymphoma?
AMITKUMAR MEHTA, MD: Loncastuximab is an CD19 antibody-drug conjugate [ADC]. [From] the L-MIND study [NCT02399085], tafasitamab [Monjuvi] is a naked CD19 monoclonal antibody. It's just like rituximab [Rituxan], which targets CD20; tafasitamab targets CD19, but there is no payload. Loncastuximab is a step further; it has a payload attached to it, and it is a PBD payload.1 Like many other ADCs, it binds to CD19 on the surface of the malignant B cells, gets internalized, and gets degraded to release the PBD toxin, which affects the DNA and causes the apoptosis of the cell.
In the era of bispecific therapies, where we are all worried about cytokine release syndrome [CRS], hospital admission, etc, loncastuximab is a simple infusion every 3 weeks. There is no CRS and no immune effector cell–associated neurotoxicity syndrome.
How was loncastuximab studied, and how did this study design compare with the study of tafasitamab plus lenalidomide (Revlimid)?
Loncastuximab was studied, like tafasitamab, in a single-arm phase 2 study. The LOTIS-2 study [NCT03589469] enrolled patients who had relapsed/refractory disease, but they had at least 2 lines of therapy, so loncastuximab is approved in the third-line setting onwards. The only requirement for them was that if a patient had CD19-directed therapy before, they should have CD19 positivity on the surface of the malignant B cells. They also allowed patients who had prior [autologous stem cell] transplant and allogeneic transplant. There are some patients who also had chimeric antigen receptor T-cell therapy. Importantly, they allowed patients who had double or triple-hit [lymphoma] so the patient population on LOTIS-2 was different than the L-MIND study. These are more high-risk patients compared with what we saw on L-MIND. Loncastuximab was given in a 30-minute infusion every 3 weeks, and on the trial, it was continued for 1 year. For the first 2 cycles the dosage is [doubled]; for the rest, it was half the dose after the first initial higher dose. The primary end point was overall response rate.
The number of patients was higher [than in L-MIND]: 124 patients.2 There were 36 patients with a complete response, 16 who were event free for 1 year, and 11 who were event free for more than 2 years. [Investigators reported their] characteristics to give you a glimpse at those patients who remained long term in complete remission. There were 5 patients with double-hit lymphoma who were in complete remission and 16 patients who had more than 3 prior line of therapy who also were in complete remission. Even as later-line therapy, loncastuximab showed activity. Remember that these patients have high risk compared with what we saw on the L-MIND study.
What toxicities are of most concern when using loncastuximab?
Loncastuximab has a toxin, PBD, which has unique adverse events [AEs]. In all the ADCs, the AE is because of the payload. Just to give you an example, if you look at brentuximab vedotin [Adcetris], the payload is MMAE and the AE of the payload is neuropathy. One major AE of PBD is photosensitivity. These patients have extreme sensitivity to the sunlight. Skin rash can potentially happen in this patient. I saw a patient today who had skin rash. He is a [fisherman] and he's on loncastuximab and got skin rash on the sun-exposed area, [although] I've seen worse skin rash. Sun protection is very important for these patients.
This toxin can also give you pleural effusion and ascites. Third spacing [edema] is very common. The way you avoid that is these patients get dexamethasone before and for a few days after the infusion of loncastuximab. That is part of the prescribing information and part of our [management] plan. When we order this, that prescription gets filed automatically. Another thing that is important to remember is diuretics. On the trial, they used spironolactone [Aldactone] as needed for fluid accumulation. These are the 3 specific clinical AEs that you will see. One less clinically meaningful AE is GGT [gamma-glutamyl transferase] elevation, which is also part of the payload. If you monitor GGT, this patient will have elevation of GGT the majority of the time. There are dose adjustments based on the GGT elevation.3
Cytopenias are also one of the AEs for loncastuximab. If you're using loncastuximab, make sure that you closely monitor the blood counts, and if needed, you can always use growth factor support, but that's where the peripheral edema comes in. There is fluid retention, that's where dexamethasone and spironolactone or any diuretic you could use for these patients [are needed].
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
August 28th 2024During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
Read More
Participants Consider the Necessity of Chemo in HER2+ Breast Cancer
August 22nd 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.
Read More
Luspatercept in MDS Promotes Transfusion Independence and Anemia Response
August 21st 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More